ABT-199
- CAS No.
- 1257044-40-8
- Chemical Name:
- ABT-199
- Synonyms
- Venetoclax;Venclexta;ATB199;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami;GDC-0199;Venetoclax (ABT-199, GDC-0199);2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199);S8048
- CBNumber:
- CB62645962
- Molecular Formula:
- C45H50ClN7O7S
- Molecular Weight:
- 868.44
- MOL File:
- 1257044-40-8.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/12/12 15:32:36
| Melting point | >150°C (dec.) |
|---|---|
| Density | 1.340±0.06 g/cm3(Predicted) |
| storage temp. | -20°C Freezer |
| solubility | DMSO (Slightly) |
| form | Yellow solid. |
| pka | 4.09±0.10(Predicted) |
| color | Light Yellow to Yellow |
| InChIKey | LQBVNQSMGBZMKD-UHFFFAOYSA-N |
| SMILES | C(NS(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)(=O)=O)(=O)C1=CC=C(N2CCN(CC3CCC(C)(C)CC=3C3=CC=C(Cl)C=C3)CC2)C=C1OC1=CN=C2NC=CC2=C1 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H361-H372 | |||||||||
| Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P260-P264-P270-P314-P501 | |||||||||
| NFPA 704 |
|
ABT-199 Chemical Properties,Uses,Production
Description
Venetoclax, codeveloped by AbbVie (previously Abbott Laboratories) and Genentech/ Roche, was approved in the US for treatment of patients with chronic lymphocytic leukemia (CLL). To meet qualifications for venetoclax treatment, patients must have received prior therapy and possess the 17p deletion genetic mutation, as determined by USFDA testing. Venetoclax functions as a selective inhibitor of B cell lymphoma subtype 2 (BCL-2), which is often overexpressed on malignant cells and thus leads to impairment of the apoptotic pathway. Along these lines, the orally dosed small molecule drug restores the ability of malignant cells to undergo apoptosis as its mechanism of action.90 Although other BCL-2 inhibitors are known, development of similar agents such as navitoclox have been pursued and halted due to undesired inhibition of BCL-XL, leading to significant thrombocytopenia and demonstrating the need for more selective inhibitors. Venetoclax is also currently being considered for approval in Europe and Canada for similar indications and is in various stages of development for the treatment of non-Hodgkin lymphomas (NHL), acute myeloid leukemia (AML), multiple myeloma (MM), and several other disorders, either as a combination therapy or a stand-alone treatment.
Definition
ChEBI: Venetoclax is a member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. It has a role as an apoptosis inducer, an antineoplastic agent and a B-cell lymphoma 2 inhibitor. It is a member of oxanes, a N-sulfonylcarboxamide, an aromatic ether, a pyrrolopyridine, a member of monochlorobenzenes, a N-arylpiperazine, a N-alkylpiperazine and a C-nitro compound.
Metabolism
In vitro studies show that venetoclax is mainly
metabolised by cytochrome P450 CYP3A4. M27 was
identified as a major metabolite in plasma with an
inhibitory activity against BCL-2 that is at least 58-fold
lower than venetoclax in vitro.
Excretion is mainly by the faecal route (>99.9%; 20.8%
unchanged).
ABT-199 Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd | +91-4049002900 +91-4049002900 | Hyderabad, India | 165 | 58 | Inquiry |
| Alembic Pharmaceuticals Limited | +91-2652280880 +91-2652280550 | Gujarat, India | 115 | 58 | Inquiry |
| Salvavidas Pharmaceutical Pvt., Ltd. | +91-2612538898 +91-9327127459 | Gujarat, India | 34 | 58 | Inquiry |
| Basil Drugs AND Pharmaceuticals Pvt Ltd | +91-2249700250 +91-9619320820 | Mumbai, India | 108 | 58 | Inquiry |
| MSN LABORATORIES PRIVATE LTD | +91 40 30438600 | New Delhi, India | 230 | 58 | Inquiry |
| DR REDDYS LABORATORIES LTD | +91-40-49002900 | New Delhi, India | 201 | 58 | Inquiry |
| ALEMBIC PHARMACEUTICALS LTD | +91 40 23704923 / 24 / 25 | New Delhi, India | 108 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6257 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6100 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
Related articles
- BCL2 inhibitor ABT-199
- ABT-199(venetoclax, RG7601, GDC-0199) is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets whi....
- Mar 25，2025
- Mechanisms of resistance to ABT-199 in leukemia and lymphoma cell lines
- ABT-199 (Venetoclax) is a potent, orally bioavailable, selective inhibitor of BCL-2. It is approved for the treatment of first....
- Apr 2，2024
- Uses and Side effects of Venetoclax
- Venetoclax is used alone or in combination with obinutuzumab (Gazyva) or rituximab (Rituxan) to treat certain types of chronic....
- Jul 26，2022
1257044-40-8(ABT-199)Related Search:
1of4
chevron_right